Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences develops and commercializes medicines for HIV, viral hepatitis, COVID-19 and cancer. Company updates regularly cover product sales and operating results, HIV franchises such as Biktarvy, Yeztugo and lenacapavir, and clinical or regulatory activity for investigational HIV regimens that combine established antiretroviral agents with newer mechanisms.
Recurring developments also include oncology pipeline expansion through Kite cell-therapy programs, the completed acquisition of Arcellx and its investigational BCMA-directed CAR T-cell therapy anitocabtagene autoleucel for multiple myeloma, collaboration activity using real-world evidence in oncology R&D, shareholder matters, and capital-structure disclosures tied to material agreements and acquisitions.
Gilead Sciences (Nasdaq: GILD) announced a 3.8% increase in its quarterly cash dividend, raising the quarterly dividend to $0.82 per share beginning Q1 2026. The dividend is payable March 30, 2026, to holders of record as of March 13, 2026. Future dividends remain subject to Board approval.
The release also reiterates Gilead's global presence in more than 35 countries and references a planned $32 billion U.S. investment announced in 2025 to support research, jobs and preparedness.
Gilead (Nasdaq: GILD) reported full year 2025 revenue of $29.4 billion and product sales of $28.9 billion. GAAP diluted EPS was $6.78 and non-GAAP diluted EPS was $8.15. Key product moves: Biktarvy sales were $14.3 billion, Descovy $2.8 billion, and Veklury declined to $911 million. The company ended 2025 with $10.6 billion in cash and provided 2026 guidance: product sales $29.6–30.0 billion, GAAP EPS $6.75–7.15, and non-GAAP EPS $8.45–8.85.
Kite, a Gilead company (Nasdaq: GILD) announced FDA approval updating the Yescarta (axicabtagene ciloleucel) label to remove the previous Limitations of Use for patients with relapsed or refractory primary central nervous system lymphoma (R/R PCNSL).
The decision follows a Phase 1 investigator-sponsored safety study that showed a manageable safety profile with no new safety signals, supporting expanded access for this rare, aggressive form of non-Hodgkin lymphoma.
Gilead Sciences (Nasdaq: GILD) will release fourth quarter and full year 2025 financial results and guidance on Tuesday, February 10, 2026 after market close. Management will host a webcast at 4:30 p.m. ET the same day to discuss results and provide a business update.
The live webcast will be available in the Investors section of the company website and will be archived for one year. Corporate headquarters are in Foster City, California.
Gilead (NASDAQ: GILD) announced NEJM publication of positive Phase 3 ASCENT-04/KEYNOTE-D19 results showing Trodelvy plus Keytruda reduced risk of disease progression or death by 35% (HR 0.65; p<0.001) versus Keytruda plus chemotherapy in first-line PD-L1+ (CPS≥10) metastatic TNBC. Median PFS was 11.2 vs 7.8 months (Trodelvy+Keytruda vs Keytruda+chemo; n=221 vs n=222). Fewer discontinuations occurred with the Trodelvy combination (12% vs 31%). No new safety signals were identified; most frequent grade ≥3 events included neutropenia and diarrhea. Gilead has submitted supplemental applications to FDA and EMA.
OncoNano Medicine announced a research collaboration with Gilead (Nasdaq: GILD) to evaluate OncoNano’s ON-BOARD™ encapsulation technology with a Gilead drug candidate on January 6, 2026.
Terms include an upfront payment, near-term preclinical milestones, development/regulatory/commercial milestones, and royalties on net sales. Gilead may expand the collaboration by nominating another target; aggregate payments to OncoNano could reach $300 million including upfront and milestone payments, plus royalties. The work will assess stability, selectivity, and efficacy of the encapsulated asset and test ON-BOARD’s tumor-localized delivery claims.
Gilead Sciences (Nasdaq: GILD) will present at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026 beginning at 11:15 a.m. Pacific Time. The company's executives will speak and the event will be available via a live webcast at investors.gilead.com.
A replay will be available for at least 30 days after the presentation. Contact details for investor relations and public affairs are provided for follow-up information.
Assembly Biosciences (NASDAQ:ASMB) and Gilead Sciences announced Gilead exercised its option to exclusively license Assembly Bio’s HSV helicase-primase inhibitor programs, ABI-1179 and ABI-5366, for recurrent genital herpes on December 22, 2025. Assembly Bio will receive a $35 million payment reflecting an option fee net of prior accelerated funding. Gilead gains sole U.S. development and commercialization rights; Assembly Bio remains eligible for up to $330 million in milestones plus tiered royalties and a U.S. opt-in to share 40% of costs and profits.
Both candidates showed positive Phase 1b antiviral and safety data supportive of once-weekly oral dosing.
Gilead (Nasdaq: GILD) announced a three-year agreement with the U.S. government to lower medicine costs in the U.S. Key terms include discounts on certain medicines in the U.S. Medicaid program, pricing future medicines at parity with other developed nations, and a Direct-to-Patient Program to offer Hepatitis C drug Epclusa at a discounted cash price via TrumpRx.gov. The deal includes a three-year exemption from Section 232 pharmaceutical tariffs tied to further U.S. manufacturing investment. Gilead said the financial impact should be manageable in 2026 and beyond.
The company also confirmed a separate plan to invest $32 billion in U.S. manufacturing, R&D, and infrastructure over five years, projected to generate $43 billion in national economic value and create > 3,000 jobs.
Gilead Sciences (Nasdaq: GILD) announced on December 18, 2025 that Keeley Wettan is appointed Executive Vice President, General Counsel, Legal & Compliance, effective immediately.
Ms. Wettan joins the senior leadership team reporting to Chairman and CEO Daniel O’Day. She has 14 years at Gilead, previously led Global Legal Business Partners, litigation, government investigations, and corporate governance teams, and chairs the Gilead Foundation.
The company highlighted her role supporting launches including lenacapavir and noted Gilead’s 2025 $32 billion U.S. investment plan.